AUTL

Autolus Therapeutics plc

6.24 USD
+0.24 (+4.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Autolus Therapeutics plc stock is up 3.65% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 March’s closed higher than February. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jan 16:50 16 Feb, 2024 7.50 CALL 490 8
12 Feb 15:19 15 Mar, 2024 7.50 CALL 306 732
01 Mar 17:11 19 Apr, 2024 5.00 CALL 200 3

About Autolus Therapeutics plc

Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.